Proxy Votes Now

Home › Funds › EXCHANGE TRADED CONCEPTS TRUST › ROBO Global(R) Healthcare Technology and Innovation ETF

ROBO Global(R) Healthcare Technology and Innovation ETF (HTEC) proxy voting record 2025-2026

Fund family: EXCHANGE TRADED CONCEPTS TRUST · Filed by EXCHANGE TRADED CONCEPTS TRUST (CIK 1452937) · SEC series S000065730

Ticker: HTEC (C000212575)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 682 with, 7 against, 0 abstentions (not counted as with management). Shareholder proposals: 7 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with EXCHANGE TRADED CONCEPTS TRUST as a whole

The same two figures as EXCHANGE TRADED CONCEPTS TRUST’s manager page (11,122 ballot items across 22 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsEXCHANGE TRADED CONCEPTS TRUSTItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)90.7%60590.9%9,258
Backed environmental and social shareholder proposals at US companiesn/a016.4%317

Where this fund voted differently from most EXCHANGE TRADED CONCEPTS TRUST funds

Each ballot item this fund voted is set against the votes of the other EXCHANGE TRADED CONCEPTS TRUST funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most EXCHANGE TRADED CONCEPTS TRUST funds on 5 items (9.3% of the 54 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost EXCHANGE TRADED CONCEPTS TRUST fundsMgmtResult
Bristol-Myers Squibb Company2026-05-05Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent DirectorForAGAINST — 3 of 3 EXCHANGE TRADED CONCEPTS TRUST fundsAgainstNot approved, 27.6% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Christine A. PoonAgainstFOR — 3 of 3 EXCHANGE TRADED CONCEPTS TRUST fundsAgainstElected, 76.8% support
Regeneron Pharmaceuticals, Inc.2026-06-12Election of Directors: Craig B. Thompson, M.D.AgainstFOR — 3 of 3 EXCHANGE TRADED CONCEPTS TRUST fundsAgainstElected, 79.3% support
Incyte Corporation2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerForAGAINST — 3 of 4 EXCHANGE TRADED CONCEPTS TRUST fundsForElected, 80.9% support
Globus Medical, Inc.2026-06-03Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. PfeilWithholdFOR — 3 of 4 EXCHANGE TRADED CONCEPTS TRUST fundsAgainstElected, 91.3% support

Download all 5 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 71.7% of this fund’s 689 such votes could be given a sector; the other 195 (28.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care40251.2%
Industrials5423.7%
Technology2700.0%
Miscellaneous1100.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4090
Corporate Governance815
Audit-related600
Say-on-Pay530
Compensation491
Capital Structure380
Extraordinary Transactions30
Shareholder Rights and Defenses21

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.November 12, 2025$6M20
Moderna, Inc.May 6, 2026$6M50
CareDx, Inc.June 11, 2026$3M90
Twist Bioscience CorporationFebruary 5, 2026$3M50
Axogen, Inc.June 23, 2026$2M100
Glaukos CorporationMay 28, 2026$2M40
GRAIL, Inc.June 18, 2026$2M30
Adaptive Biotechnologies CorporationJune 5, 2026$2M40

Notable votes against management

MeetingCompanyProposalFundMgmt
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
April 23, 2026IQVIA Holdings Inc.If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposalForAgainst
May 15, 2026Medpace Holdings, Inc.Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposalForAgainst
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalForAgainst
April 21, 2026Bio-Rad Laboratories, Inc.Stockholder proposal regarding dual class capital structure. Shareholder proposalForAgainst
April 28, 2026Revvity, Inc.To approve the shareholder proposal regarding Executives to Retain Significant Stock. Shareholder proposalForAgainst
April 30, 2026Boston Scientific CorporationStockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposalForAgainst

Search this fund’s votes by company

695 ballot items at 64 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, ROBO Global(R) Healthcare Technology and Innovation ETF (HTEC) voted at 64 shareholder meetings of 60 companies, on 695 ballot items in all. Where management made a recommendation, the fund followed it on 99.0% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals about as often as EXCHANGE TRADED CONCEPTS TRUST's funds as a whole (90.7% against 90.9%). It voted differently from most EXCHANGE TRADED CONCEPTS TRUST funds on 5 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of EXCHANGE TRADED CONCEPTS TRUST’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.